Teva's Copaxone Continues To Widen MS Market Lead In U.S.

The multiple sclerosis market underwent a shake-out in 2008 when Teva's Copaxone managed to pull ahead of more established beta interferon therapies, including Biogen Idec's Avonex; the drug now holds 38 percent of the nearly $4.5 billion U.S. market